Syncona has one of the largest and highest quality gene therapy platforms globally with the potential to deliver dramatic efficacy across the tens of thousands of known genetic diseases.
The Syncona team has built companies targeting genetic diseases in the key tissue compartments where gene therapy has shown dramatic patient impact. These include: the retina, the liver, the central nervous system and kidney. Our ambition is ultimately to address the most prevalent diseases in each tissue compartment.
value of gene therapy portfolio
number of clinical programmes
financing rounds in year
Latest Gene Therapy insights
*Unless stated all data at 31 December 2020